Morphologic patterns associated with BRCA1 and BRCA2 genotype in ovarian carcinoma

Integrated genomic analyses of ovarian carcinoma

Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,925

Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer

Zhang, L., Conejo-Garcia, J. R., Katsaros, D., Gimotty, P. A., Massobrio, M., Regnani, G., Makrigiannakis, A., Gray, H., Schlienger, K., Liebman, M. N., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020177 · Cited by 3,397

Intraepithelial CD8+tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer

Sato, E., Olson, S. H., Ahn, J., Bundy, B., Nishikawa, H., Qian, F., Jungbluth, A. A., Frosina, D., Gnjatic, S., Ambrosone, C., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0509182102 · Cited by 2,372

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

Audeh, M. W., Carmichael, J., Penson, R. T., Friedlander, M., Powell, B., Bell-McGuinn, K. M., Scott, C., Weitzel, J. N., Oaknin, A., Loman, N., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60893-8 · Cited by 2,279

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

Tutt, A., Robson, M., Garber, J. E., Domchek, S. M., Audeh, M. W., Weitzel, J. N., Friedlander, M., Arun, B., Loman, N., Schmutzler, R. K., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60892-6 · Cited by 1,655

Programmed cell death 1 ligand 1 and tumor-infiltrating CD8 + T lymphocytes are prognostic factors of human ovarian cancer

Hamanishi, J., Mandai, M., Iwasaki, M., Okazaki, T., Tanaka, Y., Yamaguchi, K., Higuchi, T., Yagi, H., Takakura, K., Minato, N., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0611533104 · Cited by 1,378

Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses in BRCA Carrier Ovarian Cancer Correlating With Platinum-Free Interval

Fong, P. C., Yap, T. A., Boss, D. S., Carden, C. P., Mergui-Roelvink, M., Gourley, C., De Greve, J., Lubinski, J., Shanley, S., Messiou, C., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.9589 · Cited by 1,010

Prevalence and Penetrance of Germline BRCA1 and BRCA2 Mutations in a Population Series of 649 Women with Ovarian Cancer

Risch, H. A., McLaughlin, J. R., Cole, D. E. C., Rosen, B., Bradley, L., Kwan, E., Jack, E., Vesprini, D. J., Kuperstein, G., Abrahamson, J. L. A., et al. (2001) · The American Journal of Human Genetics · doi:10.1086/318787 · Cited by 986

Clinicopathologic Features of <EMPH TYPE="ITAL">BRCA</EMPH>-Linked and Sporadic Ovarian Cancer

Boyd, J. (2000) · JAMA · doi:10.1001/jama.283.17.2260 · Cited by 536

Clinical and Pathological Features of Ovarian Cancer in Women with Germ-Line Mutations of BRCA1

Rubin, S. C., Benjamin, I., Behbakht, K., Takahashi, H., Morgan, M. A., LiVolsi, V. A., Berchuck, A., Muto, M. G., Garber, J. E., Weber, B. L., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199611073351901 · Cited by 423

BRCA2 is required for ionizing radiation-induced assembly of Rad51 complex in vivo.

Yuan, S. F., Lee, S. Y., Chen, G., Song, M., Tomlinson, G. E., & Lee, E. Y.-H. P. (1999) · PubMed · Cited by 404

Mouse Model of Human Ovarian Endometrioid Adenocarcinoma Based on Somatic Defects in the Wnt/β-Catenin and PI3K/Pten Signaling Pathways

Wu, R., Hendrix-Lucas, N., Kuick, R., Zhai, Y., Schwartz, D. R., Akyol, A., Hanash, S., Misek, D. E., Katabuchi, H., Williams, B. O., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.02.016 · Cited by 313

BRCA1 up-regulation is associated with repair-mediated resistance to cis-diamminedichloroplatinum(II).

Husain, A., He, G., Venkatraman, E. S., & Spriggs, D. R. (1998) · PubMed · Cited by 291

Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities

Press, J. Z., De Luca, A., Boyd, N., Young, S., Troussard, A., Ridge, Y., Kaurah, P., Kalloger, S. E., Blood, K. A., Smith, M., et al. (2008) · BMC Cancer · doi:10.1186/1471-2407-8-17 · Cited by 287

Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss

Clarke, B., Tinker, A. V., Lee, C.-H., Subramanian, S., van de Rijn, M., Turbin, D., Kalloger, S., Han, G., Ceballos, K., Cadungog, M. G., et al. (2009) · Modern Pathology · doi:10.1038/modpathol.2008.191 · Cited by 280

The histologic phenotypes of breast carcinoma occurring before age 40 years in women with and without BRCA1 or BRCA2 germline mutations: A population-based study

Armes, J. E., Egan, A. J. M., Southey, M. C., Dite, G. S., McCredie, M. R. E., Giles, G. G., Hopper, J. L., & Venter, D. J. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19981201)83:11<2335::aid-cncr13>3.0.co;2-n · Cited by 259

Histologic Subtypes of Ovarian Carcinoma: An Overview

Soslow, R. A. (2008) · International Journal of Gynecological Pathology · doi:10.1097/pgp.0b013e31815ea812 · Cited by 258

Pathology of Ovarian Cancers in BRCA1 and BRCA2 Carriers

Lakhani, S. R., Manek, S., Penault-Llorca, F., Flanagan, A., Arnout, L., Merrett, S., McGuffog, L., Steele, D., Devilee, P., Klijn, J. G. M., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-1029-3 · Cited by 252

Tumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma

Gilks, C. B., Ionescu, D. N., Kalloger, S. E., Köbel, M., Irving, J., Clarke, B., Santos, J., Le, N., Moravan, V., & Swenerton, K. (2008) · Human Pathology · doi:10.1016/j.humpath.2008.01.003 · Cited by 242

The pathology of familial breast cancer: histological features of cancers in families not attributable to mutations in BRCA1 or BRCA2.

Lakhani, S. R., Gusterson, B. A., Jacquemier, J. D., Sloane, J. P., Anderson, T. J., van de Vijver, M. J., Venter, D. J., Freeman, A., Antoniou, A., McGuffog, L., et al. (2000) · PubMed · Cited by 222

Effect of BRCA Mutations on the Length of Survival in Epithelial Ovarian Tumors

David, Y. B. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.2.463 · Cited by 200

Constitutional Methylation of the BRCA1 Promoter Is Specifically Associated with BRCA1 Mutation-Associated Pathology in Early-Onset Breast Cancer

Wong, E. M., Southey, M. C., Fox, S. B., Brown, M. A., Dowty, J. G., Jenkins, M. A., Giles, G. G., Hopper, J. L., & Dobrovic, A. (2011) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-10-0212 · Cited by 165

Diagnosis of Ovarian Carcinoma Cell Type is Highly Reproducible: A Transcanadian Study

Köbel, M., Kalloger, S. E., Baker, P. M., Ewanowich, C. A., Arseneau, J., Zherebitskiy, V. A., Abdulkarim, S., Leung, S. C. Y., Duggan, M. A., Fontaine, D., et al. (2010) · The American Journal of Surgical Pathology · doi:10.1097/pas.0b013e3181e1a3bb · Cited by 148

Effect of BRCA Mutations on the Length of Survival in Epithelial Ovarian Tumors

David, Y. B., Chetrit, A., Hirsh‐Yechezkel, G., Friedman, E., Beck, B. D., Beller, U., Ben‐Baruch, G., Fishman, A., Levavi, H., Lubin, F., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.2.463 · Cited by 126

High-grade fimbrial-ovarian carcinomas are unified by altered p53, PTEN and PAX2 expression

Roh, M. H., Yassin, Y., Miron, A., Mehra, K. K., Mehrad, M., Monte, N. M., Mutter, G. L., Nucci, M. R., Ning, G., McKeon, F., et al. (2010) · Modern Pathology · doi:10.1038/modpathol.2010.119 · Cited by 123

Mutations of the BRCA2 gene in ovarian carcinomas.

Takahashi, H., Chiu, H. C., Bandera, C. A., Behbakht, K., Liu, P. C., Couch, F. J., Weber, B. L., LiVolsi, V. A., Furusato, M., Rebane, B. A., et al. (1996) · PubMed · Cited by 115

Survival benefit for patients with advanced-stage transitional cell carcinomas vs. other subtypes of ovarian carcinoma after chemotherapy with platinum and paclitaxel

Kommoss, F., Kommoss, S., Schmidt, D., Trunk, M. J., Pfisterer, J., & du Bois, A. (2005) · Gynecologic Oncology · doi:10.1016/j.ygyno.2004.12.047 · Cited by 60

Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer

Bowtell, D. D., Böhm, S., Ahmed, A. A., Aspuria, P.-J., Bast, R. C., Beral, V., Berek, J. S., Birrer, M. J., Blagden, S., Bookman, M. A., et al. (2015) · Nature Reviews Cancer · doi:10.1038/nrc4019 · Cited by 1,367

Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer

Konstantinopoulos, P. A., Ceccaldi, R., Shapiro, G. I., & D'Andrea, A. D. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0714 · Cited by 945

International Endocervical Adenocarcinoma Criteria and Classification (IECC): A New Pathogenetic Classification for Invasive Adenocarcinomas of the Endocervix

Stolnicu, S., Barsan, I., Hoang, L., Patel, P., Terinte, C., Pesci, A., Aviel-Ronen, S., Kiyokawa, T., Alvarado-Cabrero, I., Pike, M. C., et al. (2018) · American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000986 · Cited by 409

The role of DNA damage repair (DDR) system in response to immune checkpoint inhibitor (ICI) therapy

Shi, C., Qin, K., Lin, A., Jiang, A., Cheng, Q., Liu, Z., Zhang, J., & Luo, P. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02469-0 · Cited by 85